From April 1, 2022 to June 30, 2022, the company has repurchased 2,435,074 shares, representing 1.65% for $500.01 million. With this, the company has completed the repurchase of 10,084,005 shares, representing 6.7% for $2,700 million under the buyback announced on October 21, 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.9 USD | +3.18% | +7.47% | -19.27% |
05:33pm | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.27% | 29.48B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B | |
+2.29% | 7.67B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.